Boehringer Bails On Biosimilars Outside US

In a strategic shift confirmed by the German company, BI's Humira biosimilar Cyltezo will only be launched in the US while its version of Avastin has been abandoned altogether.

Statue of Liberty
US is land of opportunity for BI biosimilar • Source: Shutterstock

Boehringer Ingelheim GMBH has decided that its biosimilars business is going to focus on the US market and is pulling the plug on plans to develop them in the rest of the world.

The German group gave a clue that it sees its biosimilars future across the Atlantic by telling Scrip's sister publication...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.